Diagnosis & Lab Reports: Understanding Your Tests

Confirming a diagnosis of Cerebrotendinous Xanthomatosis (CTX) involves a multi-step process that looks at both the body’s chemistry and its genetic “blueprint.” Because CTX can mimic other conditions, doctors use specific lab markers to distinguish it from more common disorders.

Biochemical Markers: The Blood and Urine Tests

The first step in diagnosing CTX is often “biochemical” testing. This looks at the levels of specific substances that build up when the body cannot process cholesterol correctly.

Serum Cholestanol (Blood Test)

The most common marker is serum cholestanol. It is important to note that cholestanol is different from the “cholesterol” measured in a standard heart-health panel ^[1].

• The typical result: In most untreated CTX patients, cholestanol levels are significantly elevated—often many times higher than the normal range (which is typically below 0.6 mg/dL) ^[1][2]. Note: Normal reference ranges can vary depending on the specific laboratory’s assays and units of measurement (such as mg/dL vs. mg/L), so always refer to the reference range printed on your individual report.
• The exception: In rare “atypical” cases, a patient may have CTX but show normal or near-normal cholestanol levels ^[3][4]. If symptoms like cataracts and tendon xanthomas are present, doctors should not rely on a normal cholestanol result alone ^[3].

Urinary Bile Alcohols (Urine Test)

When cholestanol results are unclear, or to provide more evidence, doctors test for urinary bile alcohols. Because the body cannot make proper bile acids, it produces “garbage” byproducts that are excreted in the urine. One specific marker often measured is GlcA-tetrol ^[3][5]. High levels of these bile alcohols are a very sensitive indicator that the metabolic pathway is blocked ^[6][5].

Genetic Testing: The Gold Standard

While blood and urine tests point to the problem, genetic testing of the CYP27A1 gene is the only way to definitively confirm a CTX diagnosis ^[7][8].

• What it looks for: The test sequences the CYP27A1 gene to find mutations. Since CTX is autosomal recessive, a person must have two mutations (one from each parent) to have the disease ^[9][10].
• Why it matters: Genetic confirmation is essential for family planning. Because CTX is inherited, professional guidance from a Genetic Counselor is highly recommended to assist with screening asymptomatic siblings and understanding reproductive risks ^[7].

The Future: Newborn Screening

Currently, most patients are not diagnosed until they have already developed cataracts or neurological symptoms. However, scientists have developed ways to catch CTX at birth using dried blood spots (the “heel prick” test used for infants) ^[6][11]. By measuring a specific marker called 7α12αC4, it is now technically possible to identify CTX in newborns ^[12][5]. Catching the disease this early allows treatment to start before any damage to the brain or eyes occurs ^[11][13].

Completeness Checklist: Reviewing Your Reports

When you receive your medical records, use this checklist to ensure your diagnostic workup was thorough. A complete CTX evaluation should ideally include:

• [ ] Serum Cholestanol: Is the level listed, and is it compared to a reference range? (Note: It should be “cholestanol,” not “cholesterol.”)
• [ ] Urinary Bile Alcohol Profile: Did the lab look for markers like GlcA-tetrol?
• [ ] CYP27A1 Molecular Analysis: Does the report confirm two pathogenic (disease-causing) mutations in the CYP27A1 gene?
• [ ] Liver Function Tests: Especially for infants, were liver enzymes or bilirubin checked to look for neonatal cholestasis? ^[14]
• [ ] Baseline Measurements: If you have started treatment, do you have a record of your “pre-treatment” levels to compare with future tests? ^[15]

If your report is missing something, ask your doctor if it is still needed. In some cases, if genetic testing has already definitively confirmed the diagnosis, repeating older biochemical tests may not be necessary.